
The acquisition brings Gallant’s experimental stem cell treatments for feline chronic gingivostomatitis and osteoarthritis in dogs and cats into Dechra’s portfolio.
Check out this week's highlights.
As seasons change and we enter the first full day of October, we remain dedicated to delivering a robust mix of engaging veterinary news and insights right to your fingertips.
Here's a look at this week's highlights:
Stay tuned on social media and dvm360.com for more veterinary news.





